Vitruvia Medical AG Reports First Profit in 2025 and Significantly Increases Revenue
In 2025, Vitruvia Medical AG reported its first profit after taxes of CHF 308,670.73, compared to a loss of CHF 173,775.93 in the previous year.
Our subsidiary LT technologies GmbH & Co. KG generated revenue of EUR 2,540,929, compared to EUR 2,016,279 in the previous year, representing an increase of +26%. On a consolidated basis, earnings before interest, taxes, and amortization (EBITA) improved from EUR 178,398 to EUR 277,215 (a 55% increase compared to the previous year).
The investment in LT Technologies has outperformed expectations. The revenue and profit targets set for 2025 were more than met. For 2026, we anticipate continued growth in LT Technologies’ business activity, which will be reflected in its revenue and profit figures.